Dernières nouvelles du
monde de Reformulary

Reformulary 2019 Year in Review

Cannabis Standard Insights, Issue #2 published by Reformulary Group

[Anglais] CIX TOP 20 Early and CIX TOP 10 Growth announced Reformulary as a CIX TOP 20 Early, one of...

Letter to the editor: Pharmacare – not all Canadians, not all drugs

The challenges with medical cannabis in the workplace

Reformulary Group creates online community platform for info on medical cannabis

Reformulary Group launches medical cannabis formulary

Reformulary 2018 Year in Review

Canada’s first evidence-based medical cannabis formulary launches

The Reformulary, now available through Great-West Life, enhances drug plan sustainability for plan s...

La prescription d’opioïdes au Canada et sa contribution potentielle à la crise des opioïdes.

Diagnostic d'assurance-médicaments. Plus d'autres lettres à l'éditeur